These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 19860915)

  • 1. Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial.
    Behr J; Demedts M; Buhl R; Costabel U; Dekhuijzen RP; Jansen HM; MacNee W; Thomeer M; Wallaert B; Laurent F; Nicholson AG; Verbeken EK; Verschakelen J; Flower CD; Petruzzelli S; De Vuyst P; van den Bosch JM; Rodriguez-Becerra E; Lankhorst I; Sardina M; Boissard G;
    Respir Res; 2009 Oct; 10(1):101. PubMed ID: 19860915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial.
    Taniguchi H; Kondoh Y; Ebina M; Azuma A; Ogura T; Taguchi Y; Suga M; Takahashi H; Nakata K; Sato A; Sugiyama Y; Kudoh S; Nukiwa T;
    Respir Res; 2011 Jul; 12(1):93. PubMed ID: 21756364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung function outcomes in the INPULSIS
    Brown KK; Flaherty KR; Cottin V; Raghu G; Inoue Y; Azuma A; Huggins JT; Richeldi L; Stowasser S; Stansen W; Schlenker-Herceg R; Maher TM; Wells AU
    Respir Med; 2019 Jan; 146():42-48. PubMed ID: 30665517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.
    ; Martinez FJ; de Andrade JA; Anstrom KJ; King TE; Raghu G
    N Engl J Med; 2014 May; 370(22):2093-101. PubMed ID: 24836309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
    ; Raghu G; Anstrom KJ; King TE; Lasky JA; Martinez FJ
    N Engl J Med; 2012 May; 366(21):1968-77. PubMed ID: 22607134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose acetylcysteine in idiopathic pulmonary fibrosis.
    Demedts M; Behr J; Buhl R; Costabel U; Dekhuijzen R; Jansen HM; MacNee W; Thomeer M; Wallaert B; Laurent F; Nicholson AG; Verbeken EK; Verschakelen J; Flower CD; Capron F; Petruzzelli S; De Vuyst P; van den Bosch JM; Rodriguez-Becerra E; Corvasce G; Lankhorst I; Sardina M; Montanari M;
    N Engl J Med; 2005 Nov; 353(21):2229-42. PubMed ID: 16306520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis.
    Konishi S; Arita M; Ito I; Tachibana H; Takaiwa T; Fukuda Y; Watanabe N; Tsubouchi K; Masuda G; Tanaka M; Kourogi Y; Kunimasa K; Nishiyama A; Iwasaku M; Ito A; Tokioka F; Yoshioka H; Hashimoto T; Ishida T
    Intern Med; 2015; 54(22):2835-41. PubMed ID: 26567995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of TCM therapy of tonifying lung-kidney's Qi-deficiency in a case of idiopathic pulmonary fibrosis: A case report.
    Chen MJ; Yang GL; Ding YX; Tong ZQ
    Medicine (Baltimore); 2019 May; 98(18):e15140. PubMed ID: 31045757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.
    Raghu G; van den Blink B; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Santin-Janin H; Mulder GJ; Bartholmai B; Gupta R; Richeldi L
    JAMA; 2018 Jun; 319(22):2299-2307. PubMed ID: 29800034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.
    Aono Y; Nakamura Y; Kono M; Nakamura H; Yokomura K; Imokawa S; Toyoshima M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T
    Ther Adv Respir Dis; 2020; 14():1753466620953783. PubMed ID: 32928050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical use of evidence-based medicine--clinical questions: Acetylcysteine, a new treatment for an old foe?
    Bennett L; Crouse R; Feldstein D
    WMJ; 2006 Sep; 105(6):6-7. PubMed ID: 17042410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial.
    Podolanczuk AJ; Kim JS; Cooper CB; Lasky JA; Murray S; Oldham JM; Raghu G; Flaherty KR; Spino C; Noth I; Martinez FJ;
    BMC Pulm Med; 2022 Dec; 22(1):475. PubMed ID: 36514019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials.
    Kreuter M; Wuyts WA; Wijsenbeek M; Bajwah S; Maher TM; Stowasser S; Male N; Stansen W; Schoof N; Orsatti L; Swigris J
    Respir Res; 2020 Jan; 21(1):36. PubMed ID: 32000772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial.
    Hammond M; Clark AB; Cahn AP; Chilvers ER; Fraser WD; Livermore DM; Maher TM; Parfrey H; Swart AM; Stirling S; Thickett D; Whyte M; Wilson A
    Trials; 2018 Feb; 19(1):89. PubMed ID: 29402332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis.
    Homma S; Azuma A; Taniguchi H; Ogura T; Mochiduki Y; Sugiyama Y; Nakata K; Yoshimura K; Takeuchi M; Kudoh S;
    Respirology; 2012 Apr; 17(3):467-77. PubMed ID: 22257422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined pulmonary fibrosis and emphysema: a retrospective analysis of clinical characteristics, treatment and prognosis.
    Zhang L; Zhang C; Dong F; Song Q; Chi F; Liu L; Wang Y; Che C
    BMC Pulm Med; 2016 Nov; 16(1):137. PubMed ID: 27809901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.
    Costabel U; Albera C; Bradford WZ; Hormel P; King TE; Noble PW; Sahn SA; Valeyre D; du Bois RM
    Sarcoidosis Vasc Diffuse Lung Dis; 2014 Oct; 31(3):198-205. PubMed ID: 25363219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study.
    Sakamoto S; Muramatsu Y; Satoh K; Ishida F; Kikuchi N; Sano G; Sugino K; Isobe K; Takai Y; Homma S
    Respirology; 2015 Apr; 20(3):445-52. PubMed ID: 25639750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program.
    Richeldi L; du Bois RM
    Expert Rev Respir Med; 2011 Aug; 5(4):473-81. PubMed ID: 21859266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.